Testing rates recovered to pre-pandemic levels by 2021, and this may be due, in part, to the introduction by the US FDA/EMA of a recommendation for EGFR testing to be carried out in early-stage NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.